Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3b clinical ...

Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical trial titled ‘A PHASE 1, ...

Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...

Integrative approaches targeting neurological and immune pathways may help break the itch–scratch cycle in atopic dermatitis, improving pruritus, stress, sleep, and patient outcomes.

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

Severe atopic dermatitis affects at least 30 percent of the body. The size of your child’s palm is about 1 percent, he explains, so if there are 10 areas the size of their palm affected, your ...

The prevalence of atopic dermatitis is estimated to be from 10% to 20%. Most people are using the figures from 13% to 15% in the United States.

Answer: Atopic dermatitis is a very common skin disease found in both adults and children. In fact, up to 10 to 20 percent of the population at some point suffers from atopic dermatitis.

Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One. 2011;6 (4):e17520. doi: 10.1371/journal.pone ...

There’s no single test for diagnosing atopic dermatitis (eczema). Rather, your dermatologist will likely examine your skin, ask about your symptoms, and possibly run a couple tests.